CoChat

Quality of life in adults with congenital adrenal hyperplasia relates to glucocorticoid treatment, adiposity and insulin resistance: United Kingdom Congenital adrenal Hyperplasia Adult Study Executive (CaHASE)

Open access

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Abstract

CONTEXT: Quality of life (QoL) has been variously reported as normal or impaired in adults with congenital adrenal hyperplasia (CAH). To explore the reasons for this discrepancy we investigated the relationship between QoL, glucocorticoid treatment and other health outcomes in CAH adults. METHODS: Cross-sectional analysis of 151 adults with 21-hydroxylase deficiency aged 18-69 years in whom QoL (assessed using the Short Form Health Survey), glucocorticoid regimen, anthropometric and metabolic measures were recorded. Relationships were examined between QoL, type of glucocorticoid (hydrocortisone, prednisolone and dexamethasone) and dose of glucocorticoid expressed as prednisolone dose equivalent (PreDEq). QoL was expressed as z-scores calculated from matched controls (14,430 subjects from UK population). Principal components analysis (PCA) was undertaken to identify clusters of associated clinical and biochemical features and the principal component (PC) scores used in regression analysis as predictor of QoL. RESULTS: QoL scores were associated with type of glucocorticoid treatment for vitality (P=0.002) and mental health (P=0.011), with higher z-scores indicating better QoL in patients on hydrocortisone monotherapy (P<0.05). QoL did not relate to PreDEq or mutation severity. PCA identified three PCs (PC1, disease control; PC2, adiposity and insulin resistance and PC3, blood pressure and mutations) that explained 61% of the variance in observed variables. Stepwise multiple regression analysis demonstrated that PC2, reflecting adiposity and insulin resistance (waist circumference, serum triglycerides, homeostasis model assessment of insulin resistance and HDL-cholesterol), related to QoL scores, specifically impaired physical functioning, bodily pain, general health, Physical Component Summary Score (P<0.001) and vitality (P=0.002). CONCLUSIONS: Increased adiposity, insulin resistance and use of prednisolone or dexamethasone are associated with impaired QoL in adults with CAH. Intervention trials are required to establish whether choice of glucocorticoid treatment and/or weight loss can improve QoL in CAH adults.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1530/eje-13-0128

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Association between type of glucocorticoid and QoL. Boxplots representing median and interquartile ranges of QoL (SF-36) z-scores of the two QoL domains, vitality (A) and mental health (B), for CAH patients using different type of glucocorticoid treatment; whiskers represent the 5th and 95th percentiles. A z-score of 0 represents the median of the reference population. Post-hoc analysis: compared with hydrocortisone-treated patients, z-scores for vitality and mental health were lower in those treated with a combination of hydrocortisone plus prednisolone (**P<0.01), any dexamethasone combination (*P<0.05) or prednisolone (**P<0.01, for vitality only). HC, hydrocortisone; Pred, prednisolone; Dex, dexamethasone.
Figure 1 Association between type of glucocorticoid and QoL. Boxplots representing median and interquartile ranges of QoL (SF-36) z-scores of the two QoL domains, vitality (A) and mental health (B), for CAH patients using different type of glucocorticoid treatment; whiskers represent the 5th and 95th percentiles. A z-score of 0 represents the median of the reference population. Post-hoc analysis: compared with hydrocortisone-treated patients, z-scores for vitality and mental health were lower in those treated with a combination of hydrocortisone plus prednisolone (**P<0.01), any dexamethasone combination (*P<0.05) or prednisolone (**P<0.01, for vitality only). HC, hydrocortisone; Pred, prednisolone; Dex, dexamethasone.CC BY · PubMed Central
Figure 2 Association between individual components of the adiposity and insulin resistance (PC2) and physical functioning QoL. Error plots with mean and 95% confidence limits showing the size of waist circumference (A), levels of triglycerides (B), HDL cholesterol (C) and HOMA-IR (D) according to the physical functioning domain categorised into three groups based on z-scores ≥0 (n=69), <0 to −1 (n=36) and <−1 (n=46). Post-hoc analysis: **P<0.01, ***P<0.001 compared with group with z-score ≥0.
Figure 2 Association between individual components of the adiposity and insulin resistance (PC2) and physical functioning QoL. Error plots with mean and 95% confidence limits showing the size of waist circumference (A), levels of triglycerides (B), HDL cholesterol (C) and HOMA-IR (D) according to the physical functioning domain categorised into three groups based on z-scores ≥0 (n=69), <0 to −1 (n=36) and <−1 (n=46). Post-hoc analysis: **P<0.01, ***P<0.001 compared with group with z-score ≥0.CC BY · PubMed Central
Figure 3 Association between individual components of the adiposity and insulin resistance (PC2) and vitality QoL. Error plots with mean and 95% confidence limits showing the size of waist circumference (A), levels of triglycerides (B), HDL cholesterol (C) and HOMA-IR (D) according to the vitality domain categorised into three groups based on z-scores ≥0 (n=69), <0 to −1 (n=36) and <−1 (n=46). Post-hoc analysis: *P<0.05, **P<0.01 compared with group with z-score ≥0.
Figure 3 Association between individual components of the adiposity and insulin resistance (PC2) and vitality QoL. Error plots with mean and 95% confidence limits showing the size of waist circumference (A), levels of triglycerides (B), HDL cholesterol (C) and HOMA-IR (D) according to the vitality domain categorised into three groups based on z-scores ≥0 (n=69), <0 to −1 (n=36) and <−1 (n=46). Post-hoc analysis: *P<0.05, **P<0.01 compared with group with z-score ≥0.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Research works printed but not linked: 2

  1. J skel inen, 2000, Acta paediatrica (Oslo, Norway : 1992), 89, 183, 10.1080/080352500750028807 · doi:10.1080/080352500750028807 · Paper page
  2. British Medical Association and Royal Pharmaceutical Society. British National Formulary (BNF 63). British Medical Journal Publishing Group and Pharmaceutical Press, London, 2012.

Cited by

See all 79

Metadata

Authors
Han, T. S., Krone, N., Willis, D. S., Conway, G. S., Hahner, S., Rees, D. A., Stimson, R. H., Walker, B. R., Arlt, W., Ross, R. J., & _, _.
Affiliations
  • University College Hospital (GB)
  • University of Birmingham (GB)
  • Society for Endocrinology (GB)
  • University of Würzburg (DE)
  • The Queen's Medical Research Institute (GB)
  • Royal Hallamshire Hospital (GB)
Corresponding author
Ross, Richard J
Venue
European Journal of Endocrinology
Published
2013-06
Volume
168
Issue
6
Pages
887-893
ISSN
  • 0804-4643 (ISSN-L)
  • 1479-683X
OpenAlex
W2164861242
Cited by
79
References
21
Citations by year
2026: 3 · 2025: 5 · 2024: 6 · 2023: 6 · 2022: 4 · 2021: 8 · 2020: 4 · 2019: 8 · 2018: 8 · 2017: 4 · 2016: 2 · 2015: 7 · 2014: 12 · 2013: 2
FWCI
3.43
Type
journal article
Language
en
Open access
Locations
  • European Journal of Endocrinology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
  • UCL Discovery (University College London) (submittedVersion)
  • ORCA Online Research @Cardiff (Cardiff University) (submittedVersion)
  • University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
  • Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, cc-by)
  • Spiral (Imperial College London) (submittedVersion, cc-by)
Funders
  • Wellcome Trust (GR079865MA)
  • National Institute for Health and Care Research (NF-SI-0508-10356)
  • British Heart Foundation (RG/11/4/28734)
  • Society for Endocrinology
  • Medical Research Council (G0900567)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Sexual Differentiation and Disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
  • Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
Keywords
21-hydroxylase deficiency, quality of life, glucocorticoid therapy, cortisol, prednisolone, dexamethasone, adiposity, insulin resistance, waist circumference, serum triglycerides, HDL cholesterol, physical function, bodily pain, disease control, mutation severity
MeSH terms
Adrenal Hyperplasia, Congenital, Adult, Aged, Cross-Sectional Studies, Dexamethasone, Female, Glucocorticoids, United Kingdom, Humans, Insulin Resistance, Male, Middle Aged, Quality of Life, Adiposity, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Quality of life in adults with congenital adrenal hyperplasia relates to glucocorticoid treatment, adiposity and insulin resistance: United Kingdom Congenital adrenal Hyperplasia Adult Study Executive (CaHASE). https://app.cochat.ai/papers/10.1530/eje-13-0128
The paper
Han, T. S., Krone, N., Willis, D. S., Conway, G. S., Hahner, S., Rees, D. A., Stimson, R. H., Walker, B. R., Arlt, W., Ross, R. J., & _, _. (2013). Quality of life in adults with congenital adrenal hyperplasia relates to glucocorticoid treatment, adiposity and insulin resistance: United Kingdom Congenital adrenal Hyperplasia Adult Study Executive (CaHASE). European Journal of Endocrinology. https://doi.org/10.1530/eje-13-0128

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.